Abstract
The 1âyear mortality and health consequences of COVIDâ19 in cancer patients are relatively underexplored. In this multicenter cohort study, 166 COVIDâ19 patients with cancer were compared with 498 nonâcancer COVIDâ19 patients and 498 nonâCOVID cancer patients. The 1âyear allâcause mortality and hospital mortality rates in Cancer COVIDâ19 Cohort (30% and 20%) were significantly higher than those in COVIDâ19 Cohort (9% and 8%, both P < .001) and Cancer Cohort (16% and 2%, both P < 0.001). The 12âmonth allâcause postâdischarge mortality rate in survival discharged Cancer COVIDâ19 Cohort (8%) was higher than that in COVIDâ19 Cohort (0.4%, P < .001) but similar to that in Cancer Cohort (15%, P = .084). The incidence of sequelae in Cancer COVIDâ19 Cohort (23%, 26/114) is similar to that in COVIDâ19 Cohort (30%, 130/432, P = .13). The 1âyear allâcause mortality was high among patients with hematologic malignancies (59%), followed by those who have nasopharyngeal, brain, and skin tumors (45%), digestive system neoplasm (43%), and lung cancers (32%). The rate was moderate among patients with genitourinary (14%), female genital (13%), breast (11%), and thyroid tumors (0). COVIDâ19 patients with cancer showed a high rate of inâhospital mortality and 1âyear allâcause mortality, but the 12âmonth allâcause postâdischarge mortality rate in survival discharged cancer COVIDâ19 patients was similar to that in Cancer Cohort. Comparing to COVIDâ19 Cohort, risk stratification showed that hematologic, nasopharyngeal, brain, digestive system, and lung tumors were high risk (44% vs 9%, P < 0.001), while genitourinary, female genital, breast, and thyroid tumors had moderate risk (10% vs 9%, P = .85) in COVIDâ19 Cancer Cohort. Different tumor subtypes had different effects on COVIDâ19. But if cancer patients with COVIDâ19 manage to survive their COVIDâ19 infections, then longâterm mortality appears to be similar to the cancer patients without COVIDâ19, and their longâterm clinical sequelae were similar to the COVIDâ19 patients without cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.